Price Alert

Hikma Pharmaceuticals (HKMPY)

OTC: HKMPY · Real-Time Price · USD

49.25

-0.15 (-0.30%)

At close: Oct 03, 2025, 12:19 PM

49.25

0.00%

Pre-market: Oct 03, 2025, 09:44 AM EDT

Hikma Pharmaceuticals Statistics

Share Statistics

Hikma Pharmaceuticals has 110.36M shares outstanding. The number of shares has increased by -0.52% in one year.

Shares Outstanding	110.36M
Shares Change (YoY)	-0.52%
Shares Change (QoQ)	0.13%
Owned by Institutions (%)	n/a
Shares Floating	77.49M
Failed to Deliver (FTD) Shares	4,493
FTD / Avg. Volume	218.64%

Short Selling Information

The latest short interest is 2.67K, so 0% of the outstanding shares have been sold short.

Short Interest	2.67K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is 15.42 and the forward PE ratio is null. Hikma Pharmaceuticals's PEG ratio is 0.17.

PE Ratio	15.42
Forward PE	n/a
PS Ratio	1.77
Forward PS	1.6
PB Ratio	2.4
P/FCF Ratio	16.82
PEG Ratio	0.17

Financial Ratio History

Enterprise Valuation

Hikma Pharmaceuticals has an Enterprise Value (EV) of 6.65B.

EV / Sales	2.13
EV / EBITDA	9.15
EV / EBIT	11.8
EV / FCF	20.22

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.57.

Current Ratio	1.14
Quick Ratio	0.65
Debt / Equity	0.57
Debt / EBITDA	1.8
Debt / FCF	3.97
Interest Coverage	6.95

Financial Efficiency

Return on Equity is 15.54% and Return on Invested Capital is 12.79%.

Return on Equity	15.54%
Return on Assets	6.99%
Return on Invested Capital	12.79%
Revenue Per Employee	$329.16K
Profits Per Employee	$37.79K
Employee Count	9,500
Asset Turnover	0.61
Inventory Turnover	1.74

Taxes

Income Tax	93M
Effective Tax Rate	20.44%

Stock Price Statistics

The stock price has increased by -0.71% in the last 52 weeks. The beta is 0.63, so Hikma Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.63
52-Week Price Change	-0.71%
50-Day Moving Average	48.09
200-Day Moving Average	52.28
Relative Strength Index (RSI)	62.59
Average Volume (20 Days)	2,055

Income Statement

In the last 12 months, Hikma Pharmaceuticals had revenue of 3.13B and earned 359M in profits. Earnings per share was 3.24.

Revenue	3.13B
Gross Profit	1.42B
Operating Income	612M
Net Income	359M
EBITDA	727M
EBIT	530M
Earnings Per Share (EPS)	3.24

Full Income Statement

Balance Sheet

The company has 188M in cash and 1.31B in debt, giving a net cash position of -1.12B.

Cash & Cash Equivalents	188M
Total Debt	1.31B
Net Cash	-1.12B
Retained Earnings	2.36B
Total Assets	5.13B
Working Capital	285M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 564M and capital expenditures -235M, giving a free cash flow of 329M.

Operating Cash Flow	564M
Capital Expenditures	-235M
Free Cash Flow	329M
FCF Per Share	2.97

Full Cash Flow Statement

Margins

Gross margin is 45.25%, with operating and profit margins of 19.57% and 11.48%.

Gross Margin	45.25%
Operating Margin	19.57%
Pretax Margin	14.55%
Profit Margin	11.48%
EBITDA Margin	23.25%
EBIT Margin	19.57%
FCF Margin	10.52%

Dividends & Yields

HKMPY pays an annual dividend of $2.32, which amounts to a dividend yield of 3.41%.

Dividend Per Share	$2.32
Dividend Yield	3.41%
Dividend Growth (YoY)	2.13%
Payout Ratio	65.35%
Earnings Yield	6.49%
FCF Yield	5.94%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for HKMPY.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$16.2
Lynch Upside	-67.11%
Graham Number	19.52
Graham Upside	-60.37%

Scores

Altman Z-Score	3.54
Piotroski F-Score	6